Core Insights - Vietnam and Russia are enhancing cooperation in the field of biopharmaceuticals, particularly in vaccine and drug production technology transfer [1][2] - VNVC has established a nationwide service network with nearly 240 vaccination points, capable of providing tens of millions of high-quality vaccines annually [2] - VNVC's new vaccine factory is under construction and is expected to produce hundreds of millions of vaccines and bioproducts annually by the end of 2027 [2] Group 1: Cooperation Agreement - Medsintez and VNVC signed a comprehensive cooperation agreement to advance the research, production, and clinical trials of new drugs and vaccines [1] - The technology transfer includes high-tech biopharmaceuticals such as recombinant albumin, recombinant insulin, and various diabetes treatment drugs [1] - The collaboration will also focus on clinical research for the antiviral drug Triazavirin in dengue fever treatment [1] Group 2: VNVC's Capabilities and Future Plans - VNVC's new vaccine factory will start production of next-generation vaccines and advanced biopharmaceuticals from Russia and other countries by 2027 [2] - VNVC has previously signed cooperation agreements with significant partners in the biotechnology field to promote the commercialization of high-tech biopharmaceuticals, including anti-cancer mRNA vaccines [2] - Medsintez is recognized as a leading biopharmaceutical company in Russia with over 20 years of experience in drug and medical device development [2]